Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Dermatol Clin
; 33(4): 765-76, 2015 Oct.
Article
in En
| MEDLINE
| ID: mdl-26433848
ABSTRACT
Extracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to an expansion of peripheral blood dendritic cell populations and an enhanced TH1 immune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side effect profile and moderate efficacy, ECP is considered first-line therapy for erythrodermic mycosis fungoides (MF) and Sézary syndrome. Patients with a measurable but low blood tumor burden are most likely to respond to ECP, and the addition of adjunctive immunostimulatory agents may also increase response rates. There may be a role for ECP in the treatment of refractory early stage MF, but data are limited.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Mycosis Fungoides
/
Sezary Syndrome
/
Photopheresis
Limits:
Humans
Language:
En
Journal:
Dermatol Clin
Year:
2015
Document type:
Article